Free Trial

Cardiff Oncology (CRDF) Competitors

Cardiff Oncology logo
$2.19 -0.05 (-2.23%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$2.20 +0.01 (+0.50%)
As of 10/17/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRDF vs. CMPX, OPT, SVRA, KALV, BCYC, CTMX, RGNX, MNPR, PRTA, and ETON

Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Compass Therapeutics (CMPX), Opthea (OPT), Savara (SVRA), KalVista Pharmaceuticals (KALV), Bicycle Therapeutics (BCYC), CytomX Therapeutics (CTMX), REGENXBIO (RGNX), Monopar Therapeutics (MNPR), Prothena (PRTA), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.

Cardiff Oncology vs. Its Competitors

Cardiff Oncology (NASDAQ:CRDF) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Compass Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -9,344.14%. Compass Therapeutics' return on equity of -53.11% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-9,344.14% -77.94% -63.65%
Compass Therapeutics N/A -53.11%-46.14%

Cardiff Oncology currently has a consensus target price of $10.63, indicating a potential upside of 385.16%. Compass Therapeutics has a consensus target price of $13.10, indicating a potential upside of 207.51%. Given Cardiff Oncology's higher possible upside, equities research analysts clearly believe Cardiff Oncology is more favorable than Compass Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Compass Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91

In the previous week, Compass Therapeutics had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for Compass Therapeutics and 1 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.54 beat Compass Therapeutics' score of 0.20 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardiff Oncology
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Compass Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cardiff Oncology has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.

Cardiff Oncology has higher earnings, but lower revenue than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$680K214.27-$45.43M-$0.87-2.52
Compass Therapeutics$850K693.03-$49.38M-$0.45-9.47

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Compass Therapeutics beats Cardiff Oncology on 12 of the 17 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRDF vs. The Competition

MetricCardiff OncologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$145.69M$3.44B$6.19B$10.55B
Dividend YieldN/A2.28%5.70%4.81%
P/E Ratio-2.5223.0185.5427.13
Price / Sales214.27481.55610.73132.72
Price / CashN/A46.9237.1060.81
Price / Book1.1810.4112.236.52
Net Income-$45.43M-$52.77M$3.33B$276.93M
7 Day Performance-0.90%2.31%1.17%1.93%
1 Month Performance6.83%12.59%6.85%2.19%
1 Year Performance-24.48%11.18%58.93%34.62%

Cardiff Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRDF
Cardiff Oncology
2.5334 of 5 stars
$2.19
-2.2%
$10.63
+385.2%
-24.5%$145.69M$680K-2.5220
CMPX
Compass Therapeutics
2.5525 of 5 stars
$4.28
+0.9%
$13.10
+206.1%
+129.0%$586.32M$850K-9.5120News Coverage
Gap Down
OPT
Opthea
0.3579 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
-31.7%$583.10M$30K0.008News Coverage
Analyst Forecast
Gap Up
High Trading Volume
SVRA
Savara
3.0784 of 5 stars
$3.41
+1.2%
$7.50
+119.9%
-4.0%$582.46MN/A-6.8220Trending News
Analyst Upgrade
Analyst Revision
KALV
KalVista Pharmaceuticals
3.2709 of 5 stars
$11.32
-1.6%
$26.43
+133.5%
-11.2%$581.02MN/A-2.87100
BCYC
Bicycle Therapeutics
3.5397 of 5 stars
$8.12
-2.4%
$22.22
+173.7%
-69.8%$576.63M$35.28M-2.31240News Coverage
Analyst Forecast
CTMX
CytomX Therapeutics
4.3156 of 5 stars
$3.40
+1.2%
$5.42
+59.3%
+171.2%$554.11M$138.10M6.07170
RGNX
REGENXBIO
4.4363 of 5 stars
$11.34
+3.8%
$28.38
+150.2%
+5.7%$551.61M$83.33M-3.30370Gap Down
MNPR
Monopar Therapeutics
3.193 of 5 stars
$102.05
+16.2%
$105.67
+3.5%
+1,356.9%$541.85MN/A-30.6510
PRTA
Prothena
2.3424 of 5 stars
$10.35
+3.0%
$20.50
+98.1%
-42.0%$540.99M$135.16M-1.84130Analyst Revision
ETON
Eton Pharmaceuticals
2.2468 of 5 stars
$18.08
-8.0%
$29.67
+64.1%
+117.7%$527.23M$39.01M-113.0020

Related Companies and Tools


This page (NASDAQ:CRDF) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners